Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

doi:10.1172/JCI114527

Back to search

Article

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

The Journal of clinical investigation - 1 Mar 1990

Grant D M, Mörike K, Eichelbaum M, Meyer U A

Abstract excerpt

The biochemical basis underlying the genetic polymorphism of drug N-acetylation was investigated using a combination of in vivo and in vitro assays for arylamine N-acetyltransferase (NAT) activity and content in human liver. The acetylator phenotype of 26 surgical patients was determined using ca...

Topics

Acetylation
Acetyltransferases
Adult
Aged
Arylamine N-Acetyltransferase
DNA
Female
Humans
Liver
Male
Middle Aged
Phenotype
Uracil
Xanthines

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.